fda glp-1 compounding crackdown october 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of medications like semaglutide and tirzepatide, signaling a major shift in how these The GLP-1 drug shortage is

Weight comes off quickly, particularly in the first several months of treatment when tirzepatide starts working at its most effective

In some cases, its prescribed off-label for weight management

It never stays in the car unattended

Treatment decisions depend on provider evaluation and clinical appropriateness

It is structured as a demonstration program, meaning it is designed to test a new model of healthcare delivery and payment before considering broader implementation

This paper provides a thoughtful care management framework with robust medication counseling and education, which are both considered essential for payers and relevant healthcare stakeholders if they choose to cover these medications